Back to Report Store Home

Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 - Strong Late Stage Pipeline Holds Promise for Increasingly Diverse Market Landscape

  • Published: Dec-2015
  • Report Code: GBIHC377MR
  • Report Format: pdf

Description

List of Tables

Table 1: Pancreatic Cancer Therapeutics, Symptoms and Causes 13

Table 2: Pancreatic Cancer Therapeutics, Inherited Mutation Information 14

Table 3: Pancreatic Cancer Therapeutics, Common Mutations in Pancreatic Cancer 17

Table 4: Pancreatic Cancer Therapeutics, TNM Classification System 18

Table 5: Pancreatic Cancer Therapeutics, Survival by Stage 19

Table 6: Pancreatic Cancer Therapeutics: Common Endpoints in Oncology Clinical Trials and their Description 20

Table 7: Pancreatic Cancer Therapeutics, Key Molecular Targets in the Pipeline 39

Table 8: Pancreatic Cancer Therapeutics, Global, Average Clinical Trial Duration (Months), 2015 46

Table 9: Pancreatic Cancer Therapeutics, Global, Cross Analysis of Clinical Trial Failure Rate, Duration and Size by Molecule Type or Mechanism of Action and Phase, 2006–2015 55

Table 10: Pancreatic Cancer Therapeutics, Efficacy of TH-302 & Gemcitabine Combination Therapy 56

Table 11: Pancreatic Cancer Therapeutics, Efficacy of Ruxolitinib & Capecitabine Combination Therapy 60

Table 12: Pancreatic Cancer Therapeutics, Top Five European Markets, Europe Age-Standardized Incidence Rates of Pancreatic Cancer (per 100,000), 2012 80

Table 13: Pancreatic Cancer Therapeutics, Top Five European Markets, Market Revenue Table ($m), 2014–2021 83

Table 14: Pancreatic Cancer Therapeutics, Global, Developmental Pipeline, Discovery, 2015 100

Table 15: Pancreatic Cancer Therapeutics, Global, Developmental Pipeline, Preclinical 2015 103

Table 16: Pancreatic Cancer Therapeutics, Global, Developmental Pipeline, Phase I, 2015 106

Table 17: Pancreatic Cancer Therapeutics, Global, Developmental Pipeline, Phase II, 2015 109

Table 18: Pancreatic Cancer Therapeutics, Global, Developmental Pipeline, Phase III, 2015 113

Table 19: Pancreatic Cancer Therapeutics, Global, Developmental Pipeline, Pre-Registration, 2015 114

Table 20: Pancreatic Cancer Market, Global, Market Forecasts, 2014–2021 114

Table 21: Pancreatic Cancer Market, The US, Market Forecasts, 2014–2021 115

Table 22: Pancreatic Cancer Market, Canada, Market Forecasts, 2014–2021 115

Table 23: Pancreatic Cancer Market, The UK, Market Forecasts, 2014–2021 116

Table 24: Pancreatic Cancer Market, France, Market Forecasts, 2014–2021 116

Table 25: Pancreatic Cancer Market, Germany, Market Forecasts, 2014–2021 116

Table 26: Pancreatic Cancer Market, Italy, Market Forecasts, 2014–2021 117

Table 27: Pancreatic Cancer Market, Spain, Market Forecasts, 2014–2021 117

Table 28: Pancreatic Cancer Market, Japan, Market Forecasts, 2014–2021 117

Table 29: Abbreviations 132

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards